Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31537689

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Haematologica
Publication date
2020 Jun
First author
Ferrero S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Ferrero S
      type
      Author
    2. name
      Rossi D
      type
      Author
    3. name
      Rinaldi A
      type
      Author
    4. name
      Bruscaggin A
      type
      Author
    5. name
      Spina V
      type
      Author
    6. name
      Eskelund CW
      type
      Author
    7. name
      Evangelista A
      type
      Author
    8. name
      Moia R
      type
      Author
    9. name
      Kwee I
      type
      Author
    10. name
      Dahl C
      type
      Author
    11. name
      Di Rocco A
      type
      Author
    12. name
      Stefoni V
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Ferrero S
      type
      Author
    2. name
      Rossi D
      type
      Author
    3. name
      Rinaldi A
      type
      Author
    4. name
      Bruscaggin A
      type
      Author
    5. name
      Spina V
      type
      Author
    6. name
      Eskelund CW
      type
      Author
    7. name
      Evangelista A
      type
      Author
    8. name
      Moia R
      type
      Author
    9. name
      Kwee I
      type
      Author
    10. name
      Dahl C
      type
      Author
    11. name
      Di Rocco A
      type
      Author
    12. name
      Stefoni V
      type
      Author
    bibliography ids
    1. nci-bib-a8092a13c29f6a631e264259
    book metadata
    content sha256
    e5c5ae45ce69038dc57711d91ae6d8f8dc36a8855462f17b865fdc396c41ffc4
    document type
    citation
    dois
    1. 10.3324/haematol.2018.214056
    electronic publication date
    display
    2019 Sep 19
    precision
    day
    year
    2019
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:31537689
    immutable id
    pubmed:31537689@e5c5ae45ce69038dc57711d91ae6d8f8dc36a8855462f17b865fdc396c41ffc4
    journal
    abbreviation
    Haematologica
    issn electronic
    1592-8721
    issn print
    0390-6078
    issue
    6
    name
    Haematologica
    nlm unique id
    0417435
    pages
    1604-1612
    volume
    105
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      31537689
      provenance
      batch id
      23ffe1e2a9e160b6dca0
      provider
      NCBI PubMed ESummary
      record sha256
      44e9934487aadfdb27639ce1557318db9eed9df862592b7b631b313beab4a6e9
      response sha256
      d5cbfde8f87ba85b214c53aaf0e8fa33d70fec48dd4fde7745538180cd7e1841
      retrieved at
      2026-09-09T23:47:44.690737+00:00
      publication date
      display
      2020 Jun
      precision
      month
      year
      2020
      publication types
      1. Journal Article
      2. Randomized Controlled Trial
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/31537689/
      title
      KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.

      Preserved source evidence · Not medical advice